PD-1 Blockade in Chinese versus Western Patients with Melanoma.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32487680.
- Also identified by DOI 10.1158/1078-0432.CCR-20-1558 and PMC identifier 7442612.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this trial of programmed cell death-1 (PD-1) blockade with toripalimab in previously treated Chinese patients with melanoma, unique histologic and molecular features may explain why the objective response rate is lower than those defined in Western populations. This work suggests future avenues for investigating mechanisms of melanoma formation and resistance to PD-1 blockade.<i>See related article by Tang et al., p. 4250</i>.
Medical subject headings
- Melanoma
- Programmed Cell Death 1 Receptor